Market Report

Cell & Gene Therapy Market Report 2026-2036

The global cell & gene therapy market is projected to grow at a CAGR of 17.3% by 2036

SKU: PHA1385 Category: Code: PHA1385Pages: 424
Clear
โ† Back to category Biotechnology

Description

The global Cell & Gene Therapy market is expected to grow from US$25.78 billion in 2026 to US$126.86 billion by 2036, at a CAGR of 17.3%, representing strong expansion as advanced therapies move further into commercial use.

Growth is driven by rising prevalence of genetic and chronic diseases, continued progress in genomic science, and increasing clinical adoption of potentially curative therapies across oncology and rare diseases.

Access a Free Sample of This Report

Download a sample to explore:

  • Market forecasts and segment breakdowns
  • Competitive and company-level insights
  • Key trends shaping the market
  • Trade, policy, and supply chain analysis

Download Free Sample Report

 

Technological Innovation Driving Market Expansion

Advances in gene editing, viral vector development, and cell engineering are reshaping the cell & gene therapy market. Technologies such as CRISPR-based editing and next-generation CAR-T therapies are improving precision, scalability, and clinical outcomes.

At the same time, improvements in manufacturing processes and automation are helping to reduce production complexity, enabling broader commercialisation. Integration of genomic data and personalised medicine approaches is also expanding the range of treatable conditions.

Rising Incidence of Genetic Disorders Driving Market Demand

The increasing global burden of genetic and congenital disorders continues to support demand for cell & gene therapies. These treatments offer the ability to target underlying disease mechanisms rather than manage symptoms, positioning them as a transformative approach in modern medicine.

Improved diagnostics and screening are enabling earlier identification of genetic conditions, supporting patient stratification and accelerating clinical development pipelines.

High Treatment Costs Limiting Market Adoption

High upfront costs remain a key restraint. Many therapies exceed US$2 million per patient, creating affordability challenges for healthcare systems and payers.

Reimbursement frameworks are still evolving, with outcomes-based and instalment payment models gaining traction but not yet widely adopted. Delays in reimbursement decisions and limited treatment infrastructure continue to impact patient access and market uptake.

Trade, Policy & Supply Chain Dynamics

The cell & gene therapy market depends on complex global supply chains for specialised materials, reagents, and manufacturing equipment.

U.S. trade tariffs may increase costs for imported inputs and create supply chain uncertainty, particularly for smaller biotechnology firms. These pressures can affect development timelines, manufacturing capacity, and overall commercial scalability.

Commercial Impact

  • Cost and pricing pressure: High therapy costs and input prices are shaping market access
  • Supply chain shifts: Companies are investing in resilient and localised manufacturing
  • Regulatory influence: Approval processes and reimbursement frameworks remain critical
  • Competitive positioning: Firms with scalable platforms and strong pipelines are leading

Company Intelligence

The market is highly competitive, with a mix of large pharmaceutical companies and specialised biotechnology firms advancing innovation.

Leading companies are focusing on pipeline expansion, strategic partnerships, and manufacturing capabilities to strengthen their positions.

Competition is increasingly defined by:

  • Clinical pipeline strength
  • Technology platforms and innovation
  • Manufacturing scalability
  • Regulatory and commercial execution

This report analyses how competitive dynamics are evolving and where future opportunities will emerge.

Key Questions Answered

  • How is the Cell & Gene Therapy market evolving?
  • What are the key drivers and restraints shaping growth?
  • Which segments and regions will generate the most revenue?
  • How will reimbursement and pricing models evolve?
  • Who are the leading companies and what are their prospects?

Report Scope and Data Coverage

  • Global Cell & Gene Therapy market analysis
  • Revenue forecasts to 2036
  • Segment-level modelling across therapy type, indication, vector type, and end-user
  • Regional and national market forecasts
  • Competitive intelligence on leading companies

Includes both quantitative forecasting and qualitative strategic analysis.

CTA

Segmentation Framework

By Therapy Type

  • Cell Therapy
    – Stem Cell Therapy
    – CAR-T Cell Therapy
    – TCR-T Cell Therapy
    – Others
  • Gene Therapy
    – Gene Augmentation Therapy
    – Gene Inhibition Therapy
    – Gene Editing
    – Others

By Indication

  • Oncology
  • Genetic Disorders
  • Cardiovascular Disorders
  • Neurological Disorders
  • Infectious Diseases
  • Ophthalmic Disorders
  • Others

By Vector Type

  • Viral Vectors
  • Retrovirus
  • Lentivirus
  • Adenovirus
  • AAV
  • Others
    Non-viral Vectors

By End-user

  • Hospitals
  • Research Institutes
  • Pharmaceutical Companies
  • Others

Geographic Coverage

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific

  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Singapore
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America

Middle East & Africa

  • GCC
  • South Africa
  • Rest of Middle East & Africa

Cell & Gene Therapy Market Report 2026-2036
Need industry data? Please contact us today.

Company Intelligence Coverage

This report includes detailed profiles of leading companies such as:

  • Adaptimmune
  • ALLOGENE THERAPEUTICS
  • Atara Biotherapeutics, Inc.
  • Beam Therapeutics
  • BioMarin
  • Bristol-Myers Squibb Company
  • Catalent, Inc
  • CRISPR Therapeutics
  • Genetix Biotherapeutics Inc.
  • GenScript
  • Gilead Sciences, Inc.
  • Intellia Therapeutics, Inc.
  • Johnson & Johnson
  • Lonza
  • MeiraGTx Limited
  • Novartis AG
  • Sarepta Therapeutics, Inc.
  • Ultragenyx Pharmaceutical Inc.
  • Vertex Pharmaceuticals Incorporated

Each profile includes:

  • Business overview
  • Financial positioning
  • Product and technology capabilities
  • Strategic outlook

Bespoke Intelligence & Customisation

Visiongain provides tailored intelligence to support specific business needs, including custom forecasts, competitive benchmarking, and regulatory analysis.

Why This Market Intelligence Matters

  • The Cell & Gene Therapy market is entering a critical growth phase, driven by scientific breakthroughs, expanding clinical adoption, and evolving reimbursement models.
  • Organisations that understand these dynamics will be better positioned to capture opportunities, manage risk, and strengthen competitive positioning.

Access the Full Forecast and Competitive Analysis

Purchase the Cell & Gene Therapy Market Report 2026-2036ย to access the complete dataset, forecasts, and competitive analysis.

Download sample or contact us for enterprise access

 

For enterprise licensing, customised segmentation or analyst briefings, contact Visiongain directly at contactus@visiongain.com

Government Registration
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Cell & Gene Therapy Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.3 Impact Analysis
3.3.1 Market Driving Factors
3.3.1.1 Rising Prevalence of Genetic Disorders Fueling Advanced Therapeutic Adoption
3.3.1.2 Growing Investment in Biotechnology Research Driving Pipeline Innovation Expansion.
3.3.1.3 Increasing Regulatory Approvals, Accelerating Commercialization of Novel Therapies.
3.3.2 Market Restraining Factors
3.3.2.1 High Treatment Costs Limit Patient Accessibility and Market Penetration.
3.3.2.2 Complex Manufacturing Processes Causing Supply Chain Bottlenecks Worldwide.
3.3.2.3 Stringent Regulatory Frameworks are Delaying Product Approvals and Market Entry
3.3.3 Market Opportunities
3.3.3.1 Expanding Healthcare Infrastructure Supporting Advanced Therapy Integration Globally
3.3.3.2 Emerging Collaborations Fostering Rapid Innovation in Personalized Medicine
3.3.3.3 Technological Advancements Enabling Scalable Production of Cell-based Therapies
3.4 U.S. Tariffs: Whatโ€™s the Impact on Global Cell & Gene Therapy Market?
3.4.1 Overview
3.4.2 V-Shaped Recovery Scenario
3.4.2.1 Why V-Shaped Recovery?
3.4.2.2 Impact from Tariffs
3.4.2.3 Market Dynamics and Demand Recovery
3.4.2.4 Policy and Funding Support
3.4.2.5 Timeframe for Recovery
3.4.3 U-Shaped Recovery Scenario
3.4.3.1 Why U-Shaped Recovery?
3.4.3.2 Impact from Tariffs
3.4.3.3 Market Dynamics and Demand Recovery
3.4.3.4 Policy and Funding Support
3.4.3.5 Timeframe for Recovery
3.4.4 L Shaped Recovery Scenario
3.4.4.1 Why L-Shaped Recovery?
3.4.4.2 Impact from Tariffs
3.4.4.3 Market Dynamics and Demand Recovery
3.4.4.4 Policy and Funding Support
3.4.4.5 Timeframe for Recovery
3.4.5 What Strategic Considerations Should Clients Factor into Their Near-term (2026โ€“2030) and Long-term (2031โ€“2036) Planning?
3.4.6 Impact of U.S. and China Trade War on Cell & Gene Therapy Market
3.4.7 How Might the Most Impacted Countries Experience Positive and Negative Effects Resulting from These Policy Changes?
3.4.8 Global Market Tariff Sensitivity and Margin Pressure Analysis
3.5 Porterโ€™s Five Forces Analysis
3.5.1 Bargaining Power of Suppliers
3.5.2 Bargaining Power of Buyers
3.5.3 Competitive Rivalry
3.5.4 Threat of Substitutes
3.5.5 Threat of New Entrants
3.6 PEST Analysis

4 Cell & Gene Therapy Market Analysis by Therapy Type
4.1 Key Findings
4.2 Therapy Type Segment: Market Attractiveness Index
4.3 Cell & Gene Therapy Market Size Estimation and Forecast by Therapy Type
4.4 Cell Therapy
4.4.1 Market Size by Region, 2026-2036 (US$ Billion)
4.4.2 Market Share by Region, 2026 & 2036 (%)
4.4.3 Stem Cell Therapy
4.4.3.1 Market Size by Region, 2026-2036 (US$ Billion)
4.4.3.2 Market Share by Region, 2026 & 2036 (%)
4.4.4 CAR-T Cell Therapy
4.4.4.1 Market Size by Region, 2026-2036 (US$ Billion)
4.4.4.2 Market Share by Region, 2026 & 2036 (%)
4.4.5 TCR-T Cell Therapy
4.4.5.1 Market Size by Region, 2026-2036 (US$ Billion)
4.4.5.2 Market Share by Region, 2026 & 2036 (%)
4.4.6 Others
4.4.6.1 Market Size by Region, 2026-2036 (US$ Billion)
4.4.6.2 Market Share by Region, 2026 & 2036 (%)
4.5 Gene Therapy
4.5.1 Market Size by Region, 2026-2036 (US$ Billion)
4.5.2 Market Share by Region, 2026 & 2036 (%)
4.5.3 Gene Augmentation Therapy
4.5.3.1 Market Size by Region, 2026-2036 (US$ Billion)
4.5.3.2 Market Share by Region, 2026 & 2036 (%)
4.5.4 Gene Inhibition Therapy
4.5.4.1 Market Size by Region, 2026-2036 (US$ Billion)
4.5.4.2 Market Share by Region, 2026 & 2036 (%)
4.5.5 Gene Editing
4.5.5.1 Market Size by Region, 2026-2036 (US$ Billion)
4.5.5.2 Market Share by Region, 2026 & 2036 (%)
4.5.6 Others
4.5.6.1 Market Size by Region, 2026-2036 (US$ Billion)
4.5.6.2 Market Share by Region, 2026 & 2036 (%)

5 Cell & Gene Therapy Market Analysis by Indication
5.1 Key Findings
5.2 Therapy Type Segment: Market Attractiveness Index
5.3 Cell & Gene Therapy Market Size Estimation and Forecast by Indication
5.4 Oncology
5.4.1 Market Size by Region, 2026-2036 (US$ Billion)
5.4.2 Market Share by Region, 2026 & 2036 (%)
5.5 Genetic Disorders
5.5.1 Market Size by Region, 2026-2036 (US$ Billion)
5.5.2 Market Share by Region, 2026 & 2036 (%)
5.6 Cardiovascular Disorders
5.6.1 Market Size by Region, 2026-2036 (US$ Billion)
5.6.2 Market Share by Region, 2026 & 2036 (%)
5.7 Neurological Disorders
5.7.1 Market Size by Region, 2026-2036 (US$ Billion)
5.7.2 Market Share by Region, 2026 & 2036 (%)
5.8 Infectious Diseases
5.8.1 Market Size by Region, 2026-2036 (US$ Billion)
5.8.2 Market Share by Region, 2026 & 2036 (%)
5.9 Ophthalmic Disorders
5.9.1 Market Size by Region, 2026-2036 (US$ Billion)
5.9.2 Market Share by Region, 2026 & 2036 (%)
5.10 Others
5.10.1 Market Size by Region, 2026-2036 (US$ Billion)
5.10.2 Market Share by Region, 2026 & 2036 (%)

6 Cell & Gene Therapy Market Analysis by Vector Type
6.1 Key Findings
6.2 Vector Type Segment: Market Attractiveness Index
6.3 Cell & Gene Therapy Market Size Estimation and Forecast by Vector Type
6.4 Viral Vectors
6.4.1 Market Size by Region, 2026-2036 (US$ Billion)
6.4.2 Market Share by Region, 2026 & 2036 (%)
6.4.3 Retrovirus
6.4.3.1 Market Size by Region, 2026-2036 (US$ Billion)
6.4.3.2 Market Share by Region, 2026 & 2036 (%)
6.4.4 Lentivirus
6.4.4.1 Market Size by Region, 2026-2036 (US$ Billion)
6.4.4.2 Market Share by Region, 2026 & 2036 (%)
6.4.5 Adenovirus
6.4.5.1 Market Size by Region, 2026-2036 (US$ Billion)
6.4.5.2 Market Share by Region, 2026 & 2036 (%)
6.4.6 AAV (Adeno-associated virus)
6.4.6.1 Market Size by Region, 2026-2036 (US$ Billion)
6.4.6.2 Market Share by Region, 2026 & 2036 (%)
6.4.7 Others
6.4.7.1 Market Size by Region, 2026-2036 (US$ Billion)
6.4.7.2 Market Share by Region, 2026 & 2036 (%)
6.5 Non-viral Vectors
6.5.1 Market Size by Region, 2026-2036 (US$ Billion)
6.5.2 Market Share by Region, 2026 & 2036 (%)

7 Cell & Gene Therapy Market Analysis by End User
7.1 Key Findings
7.2 End-user Segment: Market Attractiveness Index
7.3 Cell & Gene Therapy Market Size Estimation and Forecast by End-user
7.4 Hospitals
7.4.1 Market Size by Region, 2026-2036 (US$ Billion)
7.4.2 Market Share by Region, 2026 & 2036 (%)
7.5 Research Institutes
7.5.1 Market Size by Region, 2026-2036 (US$ Billion)
7.5.2 Market Share by Region, 2026 & 2036 (%)
7.6 Pharmaceutical Companies
7.6.1 Market Size by Region, 2026-2036 (US$ Billion)
7.6.2 Market Share by Region, 2026 & 2036 (%)
7.7 Others
7.7.1 Market Size by Region, 2026-2036 (US$ Billion)
7.7.2 Market Share by Region, 2026 & 2036 (%)

8 Cell & Gene Therapy Market Analysis by Region
8.1 Key Findings
8.2 Regional Market Size Estimation and Forecast

9 North America Cell & Gene Therapy Market Analysis
9.1 Key Findings
9.2 North America Cell & Gene Therapy Market Attractiveness Index
9.3 North America Cell & Gene Therapy Market by Country, 2026, 2031 & 2036 (US$ Billion)
9.4 North America Cell & Gene Therapy Market Size Estimation and Forecast by Country
9.5 North America Cell & Gene Therapy Market Size Estimation and Forecast by Therapy Type
9.6 North America Cell & Gene Therapy Market Size Estimation and Forecast by Indication
9.7 North America Cell & Gene Therapy Market Size Estimation and Forecast by Vector Type
9.8 North America Cell & Gene Therapy Market Size Estimation and Forecast by End-user
9.9 U.S. Cell & Gene Therapy Market Analysis
9.10 Canada Cell & Gene Therapy Market Analysis

10 Europe Cell & Gene Therapy Market Analysis
10.1 Key Findings
10.2 Europe Cell & Gene Therapy Market Attractiveness Index
10.3 Europe Cell & Gene Therapy Market by Country, 2026, 2031 & 2036 (US$ Billion)
10.4 Europe Cell & Gene Therapy Market Size Estimation and Forecast by Country
10.5 Europe Cell & Gene Therapy Market Size Estimation and Forecast by Therapy Type
10.6 Europe Cell & Gene Therapy Market Size Estimation and Forecast by Indication
10.7 Europe Cell & Gene Therapy Market Size Estimation and Forecast by Vector Type
10.8 Europe Cell & Gene Therapy Market Size Estimation and Forecast by End-user
10.9 Germany Cell & Gene Therapy Market Analysis
10.10 France Cell & Gene Therapy Market Analysis
10.11 UK Cell & Gene Therapy Market Analysis
10.12 Italy Cell & Gene Therapy Market Analysis
10.13 Spain Cell & Gene Therapy Market Analysis
10.14 Russia Cell & Gene Therapy Market Analysis
10.15 Rest of Europe Cell & Gene Therapy Market Analysis

11 Asia Pacific Cell & Gene Therapy Market Analysis
11.1 Key Findings
11.2 Asia Pacific Cell & Gene Therapy Market Attractiveness Index
11.3 Asia Pacific Cell & Gene Therapy Market by Country, 2026, 2031 & 2036 (US$ Billion)
11.4 Asia-Pacific Cell & Gene Therapy Market Size Estimation and Forecast by Country
11.5 Asia Pacific Cell & Gene Therapy Market Size Estimation and Forecast by Therapy Type
11.6 Asia Pacific Cell & Gene Therapy Market Size Estimation and Forecast by Indication
11.7 Asia Pacific Cell & Gene Therapy Market Size Estimation and Forecast by Vector Type
11.8 Asia Pacific Cell & Gene Therapy Market Size Estimation and Forecast by End-user
11.9 Japan Cell & Gene Therapy Market Analysis
11.10 China Cell & Gene Therapy Market Analysis
11.11 India Cell & Gene Therapy Market Analysis
11.12 Australia Cell & Gene Therapy Market Analysis
11.13 South Korea Cell & Gene Therapy Market Analysis
11.14 Singapore Cell & Gene Therapy Market Analysis
11.15 Rest of Asia Pacific Cell & Gene Therapy Market Analysis

12 Latin America Cell & Gene Therapy Market Analysis
12.1 Key Findings
12.2 Latin America Cell & Gene Therapy Market Attractiveness Index
12.3 Latin America Cell & Gene Therapy Market by Country, 2026, 2031 & 2036 (US$ Billion)
12.4 Latin America Cell & Gene Therapy Market Size Estimation and Forecast by Country
12.5 Latin America Cell & Gene Therapy Market Size Estimation and Forecast by Therapy Type
12.6 Latin America Cell & Gene Therapy Market Size Estimation and Forecast by Indication
12.7 Latin America Cell & Gene Therapy Market Size Estimation and Forecast by Vector Type
12.8 Latin America Cell & Gene Therapy Market Size Estimation and Forecast by End-user
12.9 Brazil Cell & Gene Therapy Market Analysis
12.10 Mexico Cell & Gene Therapy Market Analysis
12.11 Argentina Cell & Gene Therapy Market Analysis
12.12 Rest of Latin America Cell & Gene Therapy Market Analysis

13 MEA Cell & Gene Therapy Market Analysis
13.1 Key Findings
13.2 MEA Cell & Gene Therapy Market Attractiveness Index
13.3 MEA Cell & Gene Therapy Market by Country, 2026, 2031 & 2036 (US$ Billion)
13.4 MEA Cell & Gene Therapy Market Size Estimation and Forecast by Country
13.5 MEA Cell & Gene Therapy Market Size Estimation and Forecast by Therapy Type
13.6 MEA Cell & Gene Therapy Market Size Estimation and Forecast by Indication
13.7 MEA Cell & Gene Therapy Market Size Estimation and Forecast by Vector Type
13.8 MEA Cell & Gene Therapy Market Size Estimation and Forecast by End-user
13.9 GCC Cell & Gene Therapy Market Analysis
13.10 South Africa Cell & Gene Therapy Market Analysis
13.11 Rest of the MEA Cell & Gene Therapy Market Analysis

14 Company Profiles
14.1 Competitive Landscape, 2026
14.2 Strategic Outlook
14.3 Adaptimmune
14.3.1 Company Snapshot
14.3.2 Company Overview
14.3.3 Financial Analysis
14.3.3.1 Net Revenue, 2021-2024
14.3.3.2 R&D, 2021-2024
14.3.4 Product Benchmarking
14.3.5 SWOT Analysis
14.3.6 Strategic Outlook
14.4 ALLOGENE THERAPEUTICS
14.4.1 Company Snapshot
14.4.2 Company Overview
14.4.3 Financial Analysis
14.4.3.1 Net Revenue, 2021-2024
14.4.3.2 R&D, 2021-2024
14.4.4 Product Benchmarking
14.4.5 SWOT Analysis
14.4.6 Strategic Outlook
14.5 Atara Biotherapeutics, Inc.
14.5.1 Company Snapshot
14.5.2 Company Overview
14.5.3 Financial Analysis
14.5.3.1 Net Revenue, 2021-2024
14.5.3.2 R&D, 2021-2024
14.5.4 Product Benchmarking
14.5.5 SWOT Analysis
14.5.6 Strategic Outlook
14.6 Beam Therapeutics
14.6.1 Company Snapshot
14.6.2 Company Overview
14.6.3 Financial Analysis
14.6.3.1 Net Revenue, 2021-2024
14.6.3.2 R&D, 2021-2024
14.6.4 Product Benchmarking
14.6.5 SWOT Analysis
14.6.6 Strategic Outlook
14.7 BioMarin
14.7.1 Company Snapshot
14.7.2 Company Overview
14.7.3 Financial Analysis
14.7.3.1 Net Revenue, 2021-2025
14.7.3.2 R&D, 2021-2025
14.7.3.3 Regional Market Shares, 2025
14.7.4 Product Benchmarking
14.7.5 SWOT Analysis
14.7.6 Strategic Outlook
14.8 Bristol-Myers Squibb Company
14.8.1 Company Snapshot
14.8.2 Company Overview
14.8.3 Financial Analysis
14.8.3.1 Net Revenue, 2021-2025
14.8.3.2 R&D, 2021-2025
14.8.3.3 Regional Market Shares, 2024
14.8.3.4 Business Segment Market Shares, 2024
14.8.4 Product Benchmarking
14.8.5 SWOT Analysis
14.8.6 Strategic Outlook
14.9 Catalent, Inc
14.9.1 Company Snapshot
14.9.2 Company Overview
14.9.3 Financial Analysis
14.9.3.1 Net Revenue, 2021-2024
14.9.3.2 Regional Market Shares, 2024
14.9.3.3 Business Segment Market Shares, 2024
14.9.4 Product Benchmarking
14.9.5 SWOT Analysis
14.9.6 Strategic Outlook
14.10 CRISPR Therapeutics
14.10.1 Company Snapshot
14.10.2 Company Overview
14.10.3 Financial Analysis
14.10.3.1 Net Revenue, 2021-2025
14.10.3.2 R&D, 2021-2024
14.10.4 Product Benchmarking
14.10.5 SWOT Analysis
14.10.6 Strategic Outlook
14.11 Genetix Biotherapeutics Inc.
14.11.1 Company Snapshot
14.11.2 Company Overview
14.11.3 Product Benchmarking
14.11.4 SWOT Analysis
14.12 GenScript
14.12.1 Company Snapshot
14.12.2 Company Overview
14.12.3 Financial Analysis
14.12.3.1 Net Revenue, 2021-2025
14.12.3.2 Regional Market Shares, 2024
14.12.3.3 Business Segment Market Shares, 2025
14.12.4 Product Benchmarking
14.12.5 SWOT Analysis
14.12.6 Strategic Outlook
14.13 Gilead Sciences, Inc.
14.13.1 Company Snapshot
14.13.2 Company Overview
14.13.3 Financial Analysis
14.13.3.1 Net Revenue, 2021-2025
14.13.3.2 R&D, 2021-2025
14.13.3.3 Regional Market Shares, 2025
14.13.3.4 Business Segment Market Shares, 2025
14.13.4 Product Benchmarking
14.13.5 SWOT Analysis
14.13.6 Strategic Outlook
14.14 Intellia Therapeutics, Inc.
14.14.1 Company Snapshot
14.14.2 Company Overview
14.14.3 Financial Analysis
14.14.3.1 Net Revenue, 2021-2024
14.14.3.2 R&D, 2021-2024
14.14.4 Product Benchmarking
14.14.5 SWOT Analysis
14.14.6 Strategic Outlook
14.15 Johnson & Johnson
14.15.1 Company Snapshot
14.15.2 Company Overview
14.15.3 Financial Analysis
14.15.3.1 Net Revenue, 2021-2025
14.15.3.2 R&D, 2021-2025
14.15.3.3 Regional Market Shares, 2025
14.15.3.4 Business Segment Market Shares, 2025
14.15.4 Product Benchmarking
14.15.5 SWOT Analysis
14.15.6 Strategic Outlook
14.16 Lonza
14.16.1 Company Snapshot
14.16.2 Company Overview
14.16.3 Financial Analysis
14.16.3.1 Net Revenue, 2021-2024
14.16.3.2 R&D, 2021-2024
14.16.3.3 Regional Market Shares, 2024
14.16.3.4 Business Segment Market Shares, 2024
14.16.4 Product Benchmarking
14.16.5 SWOT Analysis
14.16.6 Strategic Outlook
14.17 MeiraGTx Limited
14.17.1 Company Snapshot
14.17.2 Company Overview
14.17.3 Financial Analysis
14.17.3.1 Net Revenue, 2021-2024
14.17.3.2 R&D, 2021-2024
14.17.4 Product Benchmarking
14.17.5 SWOT Analysis
14.17.6 Strategic Outlook
14.18 Novartis AG
14.18.1 Company Snapshot
14.18.2 Company Overview
14.18.3 Financial Analysis
14.18.3.1 Net Revenue, 2021-2025
14.18.3.2 R&D, 2021-2025
14.18.3.3 Regional Market Shares, 2025
14.18.3.4 Business Segment Market Shares, 2025
14.18.4 Product Benchmarking
14.18.5 SWOT Analysis
14.18.6 Strategic Outlook
14.19 Sarepta Therapeutics, Inc.
14.19.1 Company Snapshot
14.19.2 Company Overview
14.19.3 Financial Analysis
14.19.3.1 Net Revenue, 2021-2024
14.19.3.2 R&D, 2021-2024
14.19.3.3 Business Segment Market Shares, 2024
14.19.4 Product Benchmarking
14.19.5 SWOT Analysis
14.19.6 Strategic Outlook
14.20 Ultragenyx Pharmaceutical Inc.
14.20.1 Company Snapshot
14.20.2 Company Overview
14.20.3 Financial Analysis
14.20.3.1 Net Revenue, 2021-2025
14.20.3.2 R&D, 2021-2025
14.20.3.3 Regional Market Shares, 2025
14.20.4 Product Benchmarking
14.20.5 SWOT Analysis
14.20.6 Strategic Outlook
14.21 Vertex Pharmaceuticals Incorporated
14.21.1 Company Snapshot
14.21.2 Company Overview
14.21.3 Financial Analysis
14.21.3.1 Net Revenue, 2021-2025
14.21.3.2 R&D, 2021-2025
14.21.3.3 Regional Market Shares, 2024
14.21.4 Product Benchmarking
14.21.5 SWOT Analysis
14.21.6 Strategic Outlook

15 Conclusion and Recommendations
15.1 Concluding Remarks from Visiongain
15.2 Recommendations for Market Players

List of Tables
Table 1 Cell & Gene Therapy Market Snapshot, 2026 & 2036 (US$ Billion, CAGR %)
Table 2 Cell & Gene Therapy Market: International Trade Tariff Impact Recovery Scenarios Snapshot
Table 3 Cell & Gene Therapy Market Forecast by Region 2026-2036 (US$ Billion, AGR%, CAGR%), Tariff Impact: V- Shaped Recovery Scenario
Table 4 Cell & Gene Therapy Market Forecast by Region 2026-2036 (US$ Billion, AGR%, CAGR%), Tariff Impact: U- Shaped Recovery Scenario
Table 5 Cell & Gene Therapy Market Forecast by Region 2026-2036 (US$ Billion, AGR%, CAGR%), Tariff Impact: L- Shaped Recovery Scenario
Table 6 Cell & Gene Therapy Market Forecast by Therapy Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 7 Cell & Gene Therapy Market Forecast by Cell Therapy, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 8 Cell Therapy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 9 Stem Cell Therapy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 10 CAR-T Cell Therapy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 11 TCR-T Cell Therapy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 12 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 13 Cell & Gene Therapy Market Forecast by Gene Therapy, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 14 Gene Therapy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 15 Gene Augmentation Therapy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 16 Gene Inhibition Therapy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 17 Gene Editing Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 18 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 19 Cell & Gene Therapy Market Forecast by Indication, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 20 Oncology Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 21 Genetic Disorders Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 22 Cardiovascular Disorders Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 23 Neurological Disorders Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 24 Infectious Diseases Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 25 Ophthalmic Disorders Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 26 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 27 Cell & Gene Therapy Market Forecast by Vector Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 28 Cell & Gene Therapy Market Forecast by Viral Vectors, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 29 Viral Vectors Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 30 Retrovirus Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 31 Lentivirus Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 32 Adenovirus Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 33 AAV Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 34 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 35 Non-viral vectors Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 36 Cell & Gene Therapy Market Forecast by End-user, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 37 Hospitals Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 38 Research Institutes Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 39 Pharmaceutical Companies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 40 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 41 Cell & Gene Therapy Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 42 North America Cell & Gene Therapy Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 43 North America Cell & Gene Therapy Market Forecast by Therapy Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 44 North America Cell & Gene Therapy Market Forecast by Indication, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 45 North America Cell & Gene Therapy Market Forecast by Vector Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 46 North America Cell & Gene Therapy Market Forecast by End-user, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 47 U.S. Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 48 Canada Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 49 Europe Cell & Gene Therapy Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 50 Europe Cell & Gene Therapy Market Forecast by Therapy Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 51 Europe Cell & Gene Therapy Market Forecast by Indication, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 52 Europe Cell & Gene Therapy Market Forecast by Vector Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 53 Europe Cell & Gene Therapy Market Forecast by End-user, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 54 Germany Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 55 France Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 56 UK Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 57 Italy Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 58 Spain Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 59 Russia Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 60 Rest of Europe Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 61 Asia-Pacific Cell & Gene Therapy Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 62 Asia Pacific Cell & Gene Therapy Market Forecast by Therapy Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 63 Asia Pacific Cell & Gene Therapy Market Forecast by Indication, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 64 Asia Pacific Cell & Gene Therapy Market Forecast by Vector Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 65 Asia Pacific Cell & Gene Therapy Market Forecast by End-user, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 66 Japan Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 67 China Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 68 India Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 69 Australia Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 70 South Korea Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 71 Singapore Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 72 Rest of Asia Pacific Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 73 Latin America Cell & Gene Therapy Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 74 Latin America Cell & Gene Therapy Market Forecast by Therapy Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 75 Latin America Cell & Gene Therapy Market Forecast by Indication, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 76 Latin America Cell & Gene Therapy Market Forecast by Vector Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 77 Latin America Cell & Gene Therapy Market Forecast by End-user, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 78 Brazil Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 79 Mexico Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 80 Argentina Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 81 Rest of Latin America Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 82 MEA Cell & Gene Therapy Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 83 MEA Cell & Gene Therapy Market Forecast by Therapy Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 84 MEA Cell & Gene Therapy Market Forecast by Indication, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 85 MEA Cell & Gene Therapy Market Forecast by Vector Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 86 MEA Cell & Gene Therapy Market Forecast by End-user, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 87 GCC Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 88 South Africa Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 89 Rest of the MEA Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
Table 90 Strategic Outlook
Table 91 Adaptimmune: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 92 Adaptimmune: Product Benchmarking
Table 93 Adaptimmune: SWOT Analysis
Table 94 Adaptimmune: Strategic Outlook
Table 95 ALLOGENE THERAPEUTICS: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 ALLOGENE THERAPEUTICS: Product Benchmarking
Table 97 ALLOGENE THERAPEUTICS: SWOT Analysis
Table 98 ALLOGENE THERAPEUTICS: Strategic Outlook
Table 99 Atara Biotherapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 100 Atara Biotherapeutics: Product Benchmarking
Table 101 Atara Biotherapeutics: SWOT Analysis
Table 102 Atara Biotherapeutics: Strategic Outlook
Table 103 Beam Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 104 Beam Therapeutics: Product Benchmarking
Table 105 Beam Therapeutics: SWOT Analysis
Table 106 Beam Therapeutics: Strategic Outlook
Table 107 BioMarin: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 108 BioMarin: Product Benchmarking
Table 109 BioMarin: SWOT Analysis
Table 110 BioMarin: Strategic Outlook
Table 111 Bristol-Myers Squibb Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 112 Bristol-Myers Squibb Company: Product Benchmarking
Table 113 Bristol-Myers Squibb: SWOT Analysis
Table 114 Bristol-Myers Squibb: Strategic Outlook
Table 115 Catalent, Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 116 Catalent, Inc: Product Benchmarking
Table 117 Catalent, Inc: SWOT Analysis
Table 118 Catalent, Inc: Strategic Outlook
Table 119 CRISPR Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 120 CRISPR Therapeutics: Product Benchmarking
Table 121 CRISPR Therapeutics: SWOT Analysis
Table 122 CRISPR Therapeutics: Strategic Outlook
Table 123 Genetix Biotherapeutics Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 124 Genetix Biotherapeutics Inc.: Product Benchmarking
Table 125 Genetix Biotherapeutics Inc.: SWOT Analysis
Table 126 GenScript: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 127 GenScript: Product Benchmarking
Table 128 GenScript: SWOT Analysis
Table 129 Genetix Biotherapeutics Inc.: Strategic Outlook
Table 130 Gilead Sciences, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 131 Gilead Sciences, Inc.: Product Benchmarking
Table 132 Gilead Sciences, Inc.: SWOT Analysis
Table 133 Gilead Sciences, Inc.: Strategic Outlook
Table 134 Intellia Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 135 Intellia Therapeutics, Inc.: Product Benchmarking
Table 136 Intellia Therapeutics, Inc.: SWOT Analysis
Table 137 Intellia Therapeutics, Inc.: Strategic Outlook
Table 138 Johnson & Johnson: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 139 Johnson & Johnson: Product Benchmarking
Table 140 Johnson & Johnson: SWOT Analysis
Table 141 Johnson & Johnson: Strategic Outlook
Table 142 Lonza: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 143 Lonza: Product Benchmarking
Table 144 Lonza: SWOT Analysis
Table 145 Lonza: Strategic Outlook
Table 146 MeiraGTx Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 147 MeiraGTx Limited: Product Benchmarking
Table 148 MeiraGTx Limited: SWOT Analysis
Table 149 MeiraGTx Limited: Strategic Outlook
Table 150 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 151 Novartis AG: Product Benchmarking
Table 152 Novartis AG: SWOT Analysis
Table 153 Novartis AG: Strategic Outlook
Table 154 Sarepta Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 155 Sarepta Therapeutics, Inc.: Product Benchmarking
Table 156 Sarepta Therapeutics, Inc.: SWOT Analysis
Table 157 Sarepta Therapeutics, Inc.: Strategic Outlook
Table 158 Ultragenyx Pharmaceutical Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 159 Ultragenyx Pharmaceutical Inc.: Product Benchmarking
Table 160 Ultragenyx Pharmaceutical Inc.: SWOT Analysis
Table 161 Ultragenyx Pharmaceutical Inc.: Strategic Outlook
Table 162 Vertex Pharmaceuticals Incorporated: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 163 Vertex Pharmaceuticals Incorporated: Product Benchmarking
Table 164 Vertex Pharmaceuticals Incorporated: SWOT Analysis
Table 165 Vertex Pharmaceuticals Incorporated: Strategic Outlook

List of Figures
Figure 1 Cell & Gene Therapy Market Segmentation
Figure 2 Cell & Gene Therapy Market by Therapy Type: Market Attractiveness Index
Figure 3 Cell & Gene Therapy Market by Indication: Market Attractiveness Index
Figure 4 Cell & Gene Therapy Market by Vector Type: Market Attractiveness Index
Figure 5 Cell & Gene Therapy Market by End User: Market Attractiveness Index
Figure 6 Cell & Gene Therapy Market Attractiveness Index by Region
Figure 7 Cell & Gene Therapy Market: Market Dynamics
Figure 8 Cell & Gene Therapy Market: Impact Analysis
Figure 9 Cell & Gene Therapy Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: V-Shaped Recovery Scenario
Figure 10 Cell & Gene Therapy Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: U-Shaped Recovery Scenario
Figure 11 Cell & Gene Therapy Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: L-Shaped Recovery Scenario
Figure 12 Short Term & Long Term Planning
Figure 13 Impact of U.S. and China Trade War
Figure 14 Most Impacted Countries
Figure 15 Global Market Tariff Sensitivity and Margin Pressure Analysis
Figure 16 Cell & Gene Therapy Market: Porterโ€™s Five Forces Analysis
Figure 17 Cell & Gene Therapy Market: PEST Analysis
Figure 18 Cell & Gene Therapy Market by Therapy Type: Market Attractiveness Index
Figure 19 Cell & Gene Therapy Market Forecast by Therapy Type, 2026-2036 (US$ Billion, AGR %)
Figure 20 Cell & Gene Therapy Market Share Forecast by Therapy Type, 2026, 2031, 2036 (%)
Figure 21 Cell Therapy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 22 Cell Therapy Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 23 Stem Cell Therapy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 24 Stem Cell Therapy Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 25 CAR-T Cell Therapy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 26 CAR-T Cell Therapy Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 27 TCR-T Cell Therapy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 28 TCR-T Cell Therapy Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 29 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 30 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 31 Gene Therapy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 32 Gene Therapy Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 33 Gene Augmentation Therapy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 34 Gene Augmentation Therapy Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 35 Gene Inhibition Therapy Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 36 Gene Inhibition Therapy Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 37 Gene Editing Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 38 Gene Editing Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 39 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 40 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 41 Cell & Gene Therapy Market by Indication: Market Attractiveness Index
Figure 42 Cell & Gene Therapy Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
Figure 43 Cell & Gene Therapy Market Share Forecast by Indication, 2026, 2031, 2036 (%)
Figure 44 Oncology Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 45 Oncology Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 46 Genetic Disorders Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 47 Genetic Disorders Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 48 Cardiovascular Disorders Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 49 Cardiovascular Disorders Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 50 Neurological Disorders Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 51 Neurological Disorders Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 52 Infectious Diseases Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 53 Infectious Diseases Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 54 Ophthalmic Disorders Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 55 Ophthalmic Disorders Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 56 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 57 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 58 Cell & Gene Therapy Market by Vector Type: Market Attractiveness Index
Figure 59 Cell & Gene Therapy Market Forecast by Vector Type, 2026-2036 (US$ Billion, AGR %)
Figure 60 Cell & Gene Therapy Market Share Forecast by Vector Type, 2026, 2031, 2036 (%)
Figure 61 Viral Vectors Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 62 Viral Vectors Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 63 Retrovirus Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 64 Retrovirus Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 65 Lentivirus Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 66 Lentivirus Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 67 Adenovirus Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 68 Adenovirus Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 69 AAV Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 70 AAV Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 71 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 72 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 73 Non-viral vectors Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 74 Non-viral vectors Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 75 Cell & Gene Therapy Market by End-user: Market Attractiveness Index
Figure 76 Cell & Gene Therapy Market Forecast by End-user, 2026-2036 (US$ Billion, AGR %)
Figure 77 Cell & Gene Therapy Market Share Forecast by End-user, 2026, 2031, 2036 (%)
Figure 78 Hospitals Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 79 Hospitals Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 80 Research Institutes Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 81 Research Institutes Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 82 Pharmaceutical Companies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 83 Pharmaceutical Companies Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 84 Others Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
Figure 85 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 86 Cell & Gene Therapy Market Forecast by Region 2025 and 2035 (Revenue, CAGR%)
Figure 87 Cell & Gene Therapy Market Share Forecast by Region 2026, 2031, 2036 (%)
Figure 88 Cell & Gene Therapy Market by Region, 2026-2036 (US$ Billion, AGR %)
Figure 89 North America Cell & Gene Therapy Market Attractiveness Index
Figure 90 North America Cell & Gene Therapy Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 91 North America Cell & Gene Therapy Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 92 North America Cell & Gene Therapy Market Share Forecast by Country, 2026 & 2036 (%)
Figure 93 North America Cell & Gene Therapy Market Forecast by Therapy Type, 2026-2036 (US$ Billion, AGR %)
Figure 94 North America Cell & Gene Therapy Market Share Forecast by Therapy Type, 2026 & 2036 (%)
Figure 95 North America Cell & Gene Therapy Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
Figure 96 North America Cell & Gene Therapy Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 97 North America Cell & Gene Therapy Market Forecast by Vector Type, 2026-2036 (US$ Billion, AGR %)
Figure 98 North America Cell & Gene Therapy Market Share Forecast by Vector Type, 2026 & 2036 (%)
Figure 99 North America Cell & Gene Therapy Market Forecast by End-user, 2026-2036 (US$ Billion, AGR %)
Figure 100 North America Cell & Gene Therapy Market Share Forecast by End-user, 2026 & 2036 (%)
Figure 101 U.S. Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 102 Canada Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 103 Europe Cell & Gene Therapy Market Attractiveness Index
Figure 104 Europe Cell & Gene Therapy Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 105 Europe Cell & Gene Therapy Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 106 Europe Cell & Gene Therapy Market Share Forecast by Country, 2026 & 2036 (%)
Figure 107 Europe Cell & Gene Therapy Market Forecast by Therapy Type, 2026-2036 (US$ Billion, AGR %)
Figure 108 Europe Cell & Gene Therapy Market Share Forecast by Therapy Type, 2026 & 2036 (%)
Figure 109 Europe Cell & Gene Therapy Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
Figure 110 Europe Cell & Gene Therapy Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 111 Europe Cell & Gene Therapy Market Forecast by Vector Type, 2026-2036 (US$ Billion, AGR %)
Figure 112 Europe Cell & Gene Therapy Market Share Forecast by Vector Type, 2026 & 2036 (%)
Figure 113 Europe Cell & Gene Therapy Market Forecast by End-user, 2026-2036 (US$ Billion, AGR %)
Figure 114 Europe Cell & Gene Therapy Market Share Forecast by End-user, 2026 & 2036 (%)
Figure 115 Germany Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 116 France Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 117 UK Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 118 Italy Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 119 Spain Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 120 Russia Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 121 Rest of Europe Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 122 Asia Pacific Cell & Gene Therapy Market Attractiveness Index
Figure 123 Asia Pacific Cell & Gene Therapy Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 124 Asia Pacific Cell & Gene Therapy Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 125 Asia Pacific Cell & Gene Therapy Market Share Forecast by Country, 2026 & 2036 (%)
Figure 126 Asia Pacific Cell & Gene Therapy Market Forecast by Therapy Type, 2026-2036 (US$ Billion, AGR %)
Figure 127 Asia Pacific Cell & Gene Therapy Market Share Forecast by Therapy Type, 2026 & 2036 (%)
Figure 128 Asa Pacific Cell & Gene Therapy Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
Figure 129 Asia Pacific Cell & Gene Therapy Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 130 Asia Pacific Cell & Gene Therapy Market Forecast by Vector Type, 2026-2036 (US$ Billion, AGR %)
Figure 131 Asia Pacific Cell & Gene Therapy Market Share Forecast by Vector Type, 2026 & 2036 (%)
Figure 132 Asia Pacific Cell & Gene Therapy Market Forecast by End-user, 2026-2036 (US$ Billion, AGR %)
Figure 133 Asia Pacific Cell & Gene Therapy Market Share Forecast by End-user, 2026 & 2036 (%)
Figure 134 Japan Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 135 China Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 136 India Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 137 Australia Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 138 South Korea Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 139 Singapore Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 140 Rest of Asia Pacific Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 141 Latin America Cell & Gene Therapy Market Attractiveness Index
Figure 142 Latin America Cell & Gene Therapy Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 143 Latin America Cell & Gene Therapy Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 144 Latin America Cell & Gene Therapy Market Share Forecast by Country, 2026 & 2036 (%)
Figure 145 Latin America Cell & Gene Therapy Market Forecast by Therapy Type, 2026-2036 (US$ Billion, AGR %)
Figure 146 Latin America Cell & Gene Therapy Market Share Forecast by Therapy Type, 2026 & 2036 (%)
Figure 147 Latin America Cell & Gene Therapy Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
Figure 148 Latin America Cell & Gene Therapy Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 149 Latin America Cell & Gene Therapy Market Forecast by Vector Type, 2026-2036 (US$ Billion, AGR %)
Figure 150 Latin America Cell & Gene Therapy Market Share Forecast by Vector Type, 2026 & 2036 (%)
Figure 151 Latin America Cell & Gene Therapy Market Forecast by End-user, 2026-2036 (US$ Billion, AGR %)
Figure 152 Latin America Cell & Gene Therapy Market Share Forecast by End-user, 2026 & 2036 (%)
Figure 153 Brazil Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 154 Mexico Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 155 Argentina Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 156 Rest of Latin America Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 157 MEA Cell & Gene Therapy Market Attractiveness Index
Figure 158 MEA Cell & Gene Therapy Market by Region, 2026, 2031 & 2036 (US$ Billion)
Figure 159 MEA Cell & Gene Therapy Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
Figure 160 MEA Cell & Gene Therapy Market Share Forecast by Country, 2026 & 2036 (%)
Figure 161 MEA Cell & Gene Therapy Market Forecast by Therapy Type, 2026-2036 (US$ Billion, AGR %)
Figure 162 MEA Cell & Gene Therapy Market Share Forecast by Therapy Type, 2026 & 2036 (%)
Figure 163 MEA Cell & Gene Therapy Market Forecast by Indication, 2026-2036 (US$ Billion, AGR %)
Figure 164 MEA Cell & Gene Therapy Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 165 MEA Cell & Gene Therapy Market Forecast by Vector Type, 2026-2036 (US$ Billion, AGR %)
Figure 166 MEA & Gene Therapy Market Share Forecast by Vector Type, 2026 & 2036 (%)
Figure 167 MEA Cell & Gene Therapy Market Forecast by End-user, 2026-2036 (US$ Billion, AGR %)
Figure 168 MEA Cell & Gene Therapy Market Share Forecast by End-user, 2026 & 2036 (%)
Figure 169 GCC Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 170 South Africa Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 171 Rest of the MEA Cell & Gene Therapy Market Forecast, 2026-2036 (US$ Billion, AGR %)
Figure 172 Cell & Gene Therapy Market: Company Share/Ranking, 2026
Figure 173 Adaptimmune: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 174 Adaptimmune: R&D, 2021-2024 (US$ Million, AGR%)
Figure 175 ALLOGENE THERAPEUTICS: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 176 ALLOGENE THERAPEUTICS: R&D, 2021-2024 (US$ Million, AGR%)
Figure 177 Atara Biotherapeutics: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 178 Atara Biotherapeutics: R&D, 2021-2024 (US$ Million, AGR%)
Figure 179 Beam Therapeutics: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 180 Beam Therapeutics: R&D, 2021-2024 (US$ Million, AGR%)
Figure 181 BioMarin: Net Revenue, 2021-2025 (US$ Million, AGR%)
Figure 182 BioMarin: R&D, 2021-2025 (US$ Million, AGR%)
Figure 183 BioMarin: Regional Market Shares, 2025
Figure 184 Bristol-Myers Squibb Company.: Net Revenue, 2021-2025 (US$ Million, AGR%)
Figure 185 Bristol-Myers Squibb Company: R&D, 2021-2025 (US$ Million, AGR%)
Figure 186 Bristol-Myers Squibb Company: Regional Market Shares, 2024
Figure 187 Bristol-Myers Squibb Company: Business Segment Market Shares, 2024
Figure 188 Catalent Inc.: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 189 Catalent Inc: Regional Market Shares, 2024
Figure 190 Catalent Inc: Business Segment Market Shares, 2024
Figure 191 CRISPR Therapeutics.: Net Revenue, 2021-2025 (US$ Million, AGR%)
Figure 192 CRISPR Therapeutics.: R&D, 2021-2024 (US$ Million, AGR%)
Figure 193 GenScript.: Net Revenue, 2021-2025 (US$ Million, AGR%)
Figure 194 GenScript: Regional Market Shares, 2024
Figure 195 GenScript: Business Segment Market Shares, 2025
Figure 196 Gilead Sciences, Inc.: Net Revenue, 2021-2025 (US$ Million, AGR%)
Figure 197 Gilead Sciences, Inc.: R&D, 2021-2025 (US$ Million, AGR%)
Figure 198 Gilead Sciences, Inc.: Regional Market Shares, 2025
Figure 199 Gilead Sciences, Inc.: Business Segment Market Shares, 2025
Figure 200 Intellia Therapeutics, Inc.: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 201 Intellia Therapeutics, Inc.: R&D, 2021-2024 (US$ Million, AGR%)
Figure 202 Johnson & Johnson.: Net Revenue, 2021-2025 (US$ Million, AGR%)
Figure 203 Johnson & Johnson: R&D, 2021-2025 (US$ Million, AGR%)
Figure 204 Johnson & Johnson: Regional Market Shares, 2025
Figure 205 Johnson & Johnson: Business Segment Market Shares, 2025
Figure 206 Lonza: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 207 Lonza: R&D, 2021-2024 (US$ Million, AGR%)
Figure 208 Lonza: Regional Market Shares, 2024
Figure 209 Lonza: Business Segment Market Shares, 2024
Figure 210 MeiraGTx Limited: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 211 MeiraGTx Limited: R&D, 2021-2024 (US$ Million, AGR%)
Figure 212 Novartis AG.: Net Revenue, 2021-2025 (US$ Million, AGR%)
Figure 213 Novartis AG: R&D, 2021-2025 (US$ Million, AGR%)
Figure 214 Novartis AG: Regional Market Shares, 2025
Figure 215 Novartis AG: Business Segment Market Shares, 2025
Figure 216 Sarepta Therapeutics, Inc.: Net Revenue, 2021-2024 (US$ Million, AGR%)
Figure 217 Sarepta Therapeutics, Inc.: R&D, 2021-2024 (US$ Million, AGR%)
Figure 218 Sarepta Therapeutics, Inc.: Business Segment Market Shares, 2024
Figure 219 Ultragenyx Pharmaceutical Inc.: Net Revenue, 2021-2025 (US$ Million, AGR%)
Figure 220 Ultragenyx Pharmaceutical Inc.: R&D, 2021-2025 (US$ Million, AGR%)
Figure 221 Ultragenyx Pharmaceutical Inc.: Regional Market Shares, 2025
Figure 222 Vertex Pharmaceuticals Incorporated: Net Revenue, 2021-2025 (US$ Million, AGR%)
Figure 223 Vertex Pharmaceuticals Incorporated: R&D, 2021-2025 (US$ Million, AGR%)
Figure 224 Vertex Pharmaceuticals Incorporated: Regional Market Shares, 2024

List of Companies Profiled in the Report
Adaptimmune
ALLOGENE THERAPEUTICS
Atara Biotherapeutics, Inc.
Beam Therapeutics
BioMarin
Bristol-Myers Squibb Company
Catalent, Inc
CRISPR Therapeutics
Genetix Biotherapeutics Inc.
GenScript
Gilead Sciences, Inc.
Intellia Therapeutics, Inc.
Johnson & Johnson
Lonza
MeiraGTx Limited
Novartis AG
Sarepta Therapeutics, Inc.
Ultragenyx Pharmaceutical Inc.
Vertex Pharmaceuticals Incorporated

List of Associations
Alliance for Cancer Gene Therapy (ACGT)
Alliance for Regenerative Medicine (ARM)
Alliance for Regenerative Therapies (ART)
American Society of Gene & Cell Therapy (ASGCT)
Asia-Pacific Association for Cell and Gene Therapy (APAC-CGT)
Asia-Pacific Society for Regenerative Medicine (APSRM)
Association for Regenerative Medicine India (ARMI)
Biotechnology Innovation Organization (BIO)
California Institute for Regenerative Medicine (CIRM)
Canadian Stem Cell Network (SCN)
Cell and Gene Therapy Catapult (CGT Catapult)
European Society of Gene and Cell Therapy (ESGCT)
Foundation for the Accreditation of Cellular Therapy (FACT)
Gene Therapy Consortium (GTC)
Global Alliance for iPSC Therapies (GAiT)
International Alliance for Biological Standardization (IABS)
International Society for Cell & Gene Therapy (ISCT)
International Society for Stem Cell Research (ISSCR)
Japan Society for Gene and Cell Therapy (JSGCT)
Korea Society for Gene and Cell Therapy (KSGCT)
Regenerative Medicine Manufacturing Society (RMMS)
Standards Coordinating Body for Gene, Cell, and Regenerative Medicines and Cell-Based Drug Discovery (SCB)
Stem Cell Network Canada (SCN)
Tissue Engineering and Regenerative Medicine International Society (TERMIS)
UK BioIndustry Association (BIA)
World Health Organization (WHO)